Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System

A legfontosabb adatok

Ki végzi
Epygon
Hol
Ausztria, Olaszország, Spanyolország és Szerbia10 helyszín, 4 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
40 fő, tervezett
Kezdés
2021. febr. 1.
Várható befejezés
2029. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Epygon™ Transcatheter Mitral Valve System
A regiszteradat frissítve
2023. augusztus 7.

Ki vehet részt

Életkor
60 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients of age ≥ 60 years
  • Patients with primary or secondary severe symptomatic mitral valve regurgitation
  • Patients with severe, symptomatic mitral regurgitation and who have been evaluated by a multidisciplinary Heart Team and deemed to be ineligible for conventional valve surgery and not eligible for transcatheter repair
  • Patients with a left ventricular ejection fraction ≥ 30%
  • Patients in NYHA functional classes III to IV
  • Patients who have clearly accepted participation in this clinical study and who have signed the informed consent
  • Patients who are willing to accept and undergo all protocol related requirements
  • Patients not planning to transfer abroad

Ki nem vehet részt

  • Patients involved in other clinical assessments for drugs or devices that could interfere or alter the study endpoints
  • Patients who have previously undergone implantation of a transcatheter aortic valve prosthesis
  • Patients with previous implantation of a mitral heart valve prosthesis
  • Patients with previous implantation of a mitral annuloplasty ring
  • Patients with an active peptic ulcer or upper GI bleeding within the prior 30 days
  • Patients with any stroke within the prior 30 days
  • Patients in whom transesophageal echocardiography (TEE) is contraindicated since TEE is used for both preoperative screening and guidance during implant procedure
  • Patients with clinical/anatomical conditions unsuitable for a transapical surgical approach
  • Patients with active infection or endocarditis (suspect endocarditis included)
  • Patients which suffered an acute myocardial infarction within 30 days of the intended treatment (defined as: Q wave MI, or non-Q wave MI with elevation of CK-MB ≥ 3 times normal in the absence of pathological Q waves), if no assay for CK-MB was performed, elevation of CK level to >2 times normal without new Q waves, or elevated Troponin level is also considered a non-Q wave MI)
  • Patients with a documented allergy towards contrast media, and to any compound of the investigated medical device
  • Patients that have neurological disease severely affecting ambulation or day to day functioning
  • Patients with senile dementia, according to the advice from a specialized neurologist
  • Patients who is unwilling or deemed by the Investigator to be unwilling to comply with the requirements of the protocol, or subject with a history of non-compliance
  • Clinical exclusion criteria (preoperative screening)
  • Patients needing emergency or life-saving interventions
  • Patients with a heavily calcified mitral annulus and/or anterior mitral leaflet
  • Patients with echocardiographic evidence of intracardiac mass or thrombus
  • Patients unable to understand and sign the Informed Consent Form in absence of legal representative
  • Patients with a lack of capacity to consent
  • Patients unable to read and write; Echographic exclusion criteria (preoperative screening)
  • Patients with left ventricular apex aneurysm
  • Patients with aorto-mitral angle <120°
  • Patients with a systolic/diastolic mitral valve area assessed as not compatible with the sizing policy matrix defined by the Sponsor; Computerized Tomographic (CT) exclusion criteria (preoperative screening)
  • Patients with ventricular morphology (position of papillary muscles, ventricular wall hypertrophy) unsuitable with the study valve design
  • Patients with aorto-mitral angle <120°
  • Patients with a systolic/diastolic mitral valve area assessed as not compatible with the sizing policy matrix defined by the Sponsor

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.

A teljes eredeti leírásKevesebb

The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.

The purpose of this trial is to assess the safety and feasibility of the Epygon™ Transcatheter mitral valve and the transapical delivery system, in adult patients with severe, symptomatic mitral regurgitation.

A vizsgálat csoportja

  • Implanted patientsA vizsgált kezelés

    Implantation of Epygon mitral valve prosthesis

    Kezelés: Epygon™ Transcatheter Mitral Valve System

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System (MINERVA FIH)
A regiszteradat frissítve
2023. augusztus 7.